The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Treatment with a neutralizing anti‐murine interleukin‐17 antibody after the onset of collagen‐induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion
Abstract
Objective: Interleukin‐17 (IL‐17) is a proinflammatory cytokine that is expressed in the synovium of rheumatoid arthritis (RA) patients. This T cell cytokine is implicated in the initiation phase of arthritis. However, the role of IL‐17 during the effector phase of arthritis has still not been identified; this was the objective of the present study. Methods: Mice with collagen‐induced arthritis (CIA) were treated with polyclonal rabbit anti‐murine IL‐17 (anti–IL‐17) antibody–positive serum or normal rabbit serum after the first signs of arthritis. In addition, during a later stage of CIA mice were selected and treated with anti–IL‐17 antibody or control serum. Arthritis was monitored visually, and joint pathology was examined radiologically and histologically. Systemic IL‐6 levels were measured by enzyme‐linked immunosorbent assay, and local synovial IL‐1 and receptor activator of NF‐κB ligand (RANKL) expression was analyzed using specific immunohistochemistry. Results: Treatment with a neutralizing anti–IL‐17 antibody after the onset of CIA significantly reduced the severity of CIA. Radiographic analysis revealed marked suppression of joint damage in the knee and ankle joints. Histologic analysis confirmed the suppression of joint inflammation and showed prevention of cartilage and bone destruction after anti–IL‐17 antibody therapy. Systemic IL‐6 levels were significantly reduced after anti–IL‐17 antibody treatment. Moreover, fewer IL‐1β–positive and RANKL‐positive cells were detected in the synovium after treatment with neutralizing IL‐17. Interestingly, initiation of anti–IL‐17 antibody therapy during a later stage of CIA, using mice with higher clinical arthritis scores, still significantly slowed the progression of the disease. Conclusion: IL‐17 plays a role in early stages of arthritis, but also later during disease progression. Systemic IL‐6 was reduced and fewer synovial IL‐1–positive and RANKL‐positive cells were detected after neutralizing endogenous IL‐17 treatment, suggesting both IL‐1–dependent and IL‐1–independent mechanisms of action. Our data strongly indicate that IL‐17 neutralization could provide an additional therapeutic strategy for RA, particularly in situations in which elevated IL‐17 may attenuate the response to anti–tumor necrosis factor/anti–IL‐1 therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351
Kong, Y.-Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., Capparelli, C., Li, J., Elliott, R., McCabe, S., et al. (1999) · Nature · doi:10.1038/46303 · Cited by 1,856
Kotake, S., Udagawa, N., Takahashi, N., Matsuzaki, K., Itoh, K., Ishiyama, S., Saito, S., Inoue, K., Kamatani, N., Gillespie, M. T., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5703 · Cited by 1,696
T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines
Fossiez, F., Djossou, O., Chomarat, P., Flores-Romo, L., Ait-Yahia, S., Maat, C., Pin, J. J., Garrone, P., Garcia, E., Saeland, S., et al. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.6.2593 · Cited by 1,526
Human IL-17: a novel cytokine derived from T cells
Yao, Z., Painter, S. L., Fanslow, W. C., Ulrich, D., Macduff, B. M., Spriggs, M. K., & Armitage, R. J. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.12.5483 · Cited by 1,021
Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor
Yao, Z., Fanslow, W. C., Seldin, M. F., Rousseau, A.-M., Painter, S. L., Comeau, M. R., Cohen, J. I., & Spriggs, M. K. (1995) · Immunity · doi:10.1016/1074-7613(95)90070-5 · Cited by 994
Jovanović, D., Battista, J. A. D., Pelletier, J., Jolicoeur, F. C., He, Y., Zhang, M., Mineau, F., & Martel‐Pelletier, J. (1998) · PubMed · Cited by 973
Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium
Chabaud, M., Durand, J. M., Buchs, N., Fossiez, F., Page, G., Frappart, L., & Miossec, P. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199905)42:5<963::aid-anr15>3.0.co;2-e · Cited by 954
Arend, W. P., & Dayer, J. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380202 · Cited by 891
Jovanovic, D. V., Di Battista, J. A., Martel-Pelletier, J., Jolicoeur, F. C., He, Y., Zhang, M., Mineau, F., & Pelletier, J.-P. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.7.3513 · Cited by 867
Ziolkowska, M., Koc, A., Luszczykiewicz, G., Ksiezopolska-Pietrzak, K., Klimczak, E., Chwalinska-Sadowska, H., & Maslinski, W. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.5.2832 · Cited by 580
(2008) · Arthritis & Rheumatism · doi:10.1002/art.23363 · Cited by 505
Wong, C. K., Ho, C. Y., Li, E., & Lam, C. (2000) · Lupus · doi:10.1191/096120300678828703 · Cited by 472
Chabaud, M., Fossiez, F., Taupin, J.-L., & Miossec, P. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.1.409 · Cited by 457
Lubberts, E., Joosten, L. A. B., Oppers, B., van den Bersselaar, L., Coenen-de Roo, C. J. J., Kolls, J. K., Schwarzenberger, P., van de Loo, F. A. J., & van den Berg, W. B. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.2.1004 · Cited by 401
Self-citationJoosten, L. A. B., Helsen, M. M. A., van de Loo, F. A. J., & van den Berg, W. B. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780390513 · Cited by 400
Self-citationOsteoprotegerin Reduces Osteoclast Numbers and Prevents Bone Erosion in Collagen-Induced Arthritis
Romas, E., Sims, N. A., Hards, D. K., Lindsay, M., Quinn, J. W. M., Ryan, P. F. J., Dunstan, C. R., Martin, T. J., & Gillespie, M. T. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64417-3 · Cited by 368
Thorbecke, G. J., Shah, R., Leu, C. H., Kuruvilla, A. P., Hardison, A. M., & Palladino, M. A. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.16.7375 · Cited by 360
Schwandner, R., Yamaguchi, K., & Cao, Z. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.7.1233 · Cited by 349
Lubberts, E., van den Bersselaar, L., Oppers-Walgreen, B., Schwarzenberger, P., Coenen-de Roo, C. J. J., Kolls, J. K., Joosten, L. A. B., & van den Berg, W. B. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.5.2655 · Cited by 348
Self-citationChabaud, M., Lubberts, E., Joosten, L., van den Berg, W., & Miossec, P. (2001) · Arthritis Research & Therapy · doi:10.1186/ar294 · Cited by 333
Self-citationLubberts, E., Joosten, L. A. B., Chabaud, M., van den Bersselaar, L., Oppers, B., Coenen-de Roo, C. J. J., Richards, C. D., Miossec, P., & van den Berg, W. B. (2000) · Journal of Clinical Investigation · doi:10.1172/jci7739 · Cited by 309
Self-citationAntonysamy, M. A., Fanslow, W. C., Fu, F., Li, W., Qian, S., Troutt, A. B., & Thomson, A. W. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.1.577 · Cited by 293
Redlich, K., Hayer, S., Maier, A., Dunstan, C. R., Tohidast‐Akrad, M., Lang, S., Türk, B., Pietschmann, P., Woloszczuk, W., Haralambous, S., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10097 · Cited by 285
MOLECULAR CHARACTERIZATION OF THE HUMAN INTERLEUKIN (Il)-17 RECEPTOR
Yao, Z., Spriggs, M. K., Derry, J. M. J., Strockbine, L., Park, L. S., VandenBos, T., Zappone, J., Painter, S. L., & Armitage, R. J. (1997) · Cytokine · doi:10.1006/cyto.1997.0240 · Cited by 280
CONTRIBUTION OF INTERLEUKIN 17 TO SYNOVIUM MATRIX DESTRUCTION IN RHEUMATOID ARTHRITIS
Chabaud, M., Garnero, P., Dayer, J.-M., Guerne, P.-A., Fossiez, F., & Miossec, P. (2000) · Cytokine · doi:10.1006/cyto.2000.0681 · Cited by 277
Bush, K. A., Farmer, K. M., Walker, J. S., & Kirkham, B. W. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10173 · Cited by 252
Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment
VAN DEN BERG, W. B., JOOSTEN, L. A. B., HELSEN, M., & VAN DE LOO, F. A. J. (2008) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.1994.tb06517.x · Cited by 251
Self-citationKoshy, P. J., Henderson, N., Logan, C., Life, P. F., Cawston, T. E., & Rowan, A. D. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.8.704 · Cited by 205
Chabaud, M., & Miossec, P. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200106)44:6<1293::aid-art221>3.0.co;2-t · Cited by 197
Martel-Pelletier, J., Mineau, F., Jovanovic, D., Di Battista, J. A., & Pelletier, J.-P. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199911)42:11<2399::aid-anr19>3.0.co;2-y · Cited by 165
Benderdour, M., Tardif, G., Pelletier, J., Battista, J. A. D., Reboul, P., Ranger, P., & Martel‐Pelletier, J. (2002) · PubMed · Cited by 110
Interleukin 17 synergises with tumour necrosis factor α to induce cartilage destruction in vitro
van Bezooijen, R. L., van der Wee-Pals, L., Papapoulos, S. E., & Löwik, C. W. G. M. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.10.870 · Cited by 108
PATHWAYS BY WHICH INTERLEUKIN 17 INDUCES ARTICULAR CARTILAGE BREAKDOWN IN VITRO AND IN VIVO
Cai, L., Yin, J., Starovasnik, M. A., Hogue, D. A., Hillan, K. J., Mort, J. S., & Filvaroff, E. H. (2001) · Cytokine · doi:10.1006/cyto.2001.0939 · Cited by 107
Lubberts, E., Joosten, L. A. B., van de Loo, F. A. J., van den Bersselaar, L. A. M., & van den Berg, W. B. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200006)43:6<1300::aid-anr12>3.0.co;2-d · Cited by 101
Self-citationEffect of interleukin 17 on proteoglycan degradation in murine knee joints
Dudler, J., Renggli-Zulliger, N., Busso, N., Lotz, M., & So, A. (2000) · Annals of the Rheumatic Diseases · doi:10.1136/ard.59.7.529 · Cited by 78
Lubberts, E., Oppers‐Walgreen, B., Pettit, A. R., van den Bersselaar, L., Joosten, L. A. B., Goldring, S. R., Gravallese, E. M., & van den Berg, W. B. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10607 · Cited by 70
Self-citationIncreased Urinary Excretion of Interleukin-17 in Nephrotic Patients
Matsumoto, K., & Kanmatsuse, K. (2002) · The Nephron journals/Nephron journals · doi:10.1159/000058399 · Cited by 50
Jelaska (2000) · Pure Amsterdam UMC · doi:10.1002/1529-0131(200010)43:10 · Cited by 2
Shigeyama (2000) · doi:10.1002/1529-0131(200011)43:11
Cited by
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041257 · Cited by 4,099
Interleukin-17 Family Members and Inflammation
Kolls, J. K., & Lindén, A. (2004) · Immunity · doi:10.1016/j.immuni.2004.08.018 · Cited by 2,372
IL-17 family cytokines and the expanding diversity of effector T cell lineages
Weaver, C. T., Hatton, R. D., Mangan, P. R., & Harrington, L. E. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141557 · Cited by 1,842
The Biological Functions of T Helper 17 Cell Effector Cytokines in Inflammation
Ouyang, W., Kolls, J. K., & Zheng, Y. (2008) · Immunity · doi:10.1016/j.immuni.2008.03.004 · Cited by 1,700
Th17: An Effector CD4 T Cell Lineage with Regulatory T Cell Ties
Weaver, C. T., Harrington, L. E., Mangan, P. R., Gavrieli, M., & Murphy, K. M. (2006) · Immunity · doi:10.1016/j.immuni.2006.06.002 · Cited by 1,422
Metadata
- Authors
- Lubberts, E., Koenders, M. I., Oppers‐Walgreen, B., van den Bersselaar, L., Coenen‐de Roo, C. J. J., Joosten, L. A. B., & van den Berg, W. B.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2004-02
- Volume
- 50
- Issue
- 2
- Pages
- 650-659
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2014785961
- Cited by
- 709
- References
- 40
- FWCI
- 16.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.